Evidence map›Paper›PMID 38587648›Full record

SynthesisWorld journal of urology2024

Antibiotics efficacy in clinical and microbiological cure of uncomplicated urinary tract infection: a systematic review and network meta-analysis.

Mohammed F Hadidi, Nawaf Alhamami, Mohammed Alhakami, Ahmed S Abdulhamid, Abdullah Alsharif, Mohammed S Alomari, Yasir A Alghamdi, Samirah Alshehri, Abdullah A Ghaddaf, Faisal M Alsenani and 1 more

Abstract readSystematic ReviewNetwork Meta-Analysis
PubMed Publisher
In one paragraph

Synthesis in World journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Carbapenem-Resistant Enterobacteriaceae Bloodstream Infections in Neonates: Clinical Characteristics and Antimicrobial Therapy.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025
    Article
  5. Antimicrobial Resistance ofAntibiotics (Basel, Switzerland) · 2024
    Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Mohammed F Hadidi *College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
Nawaf Alhamami *College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
Mohammed AlhakamiCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
Ahmed S AbdulhamidCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia. Abdulhamid018@ksau-hs.edu.sa.ORCID http://orcid.org/0000-0002-1666-4907
Abdullah AlsharifCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
Mohammed S AlomariCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
Yasir A AlghamdiCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
Samirah AlshehriDepartment of Pharmacology, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
Abdullah A GhaddafCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
Faisal M AlsenaniDepartment of Urology, King Abdulaziz Medical City, National Guard Health Affairs, Jeddah, Saudi Arabia.
Hisham AlmadaniDepartment of Urology, King Abdulaziz Medical City, National Guard Health Affairs, Jeddah, Saudi Arabia.
King Saud bin Abdulaziz University for Health Sciences · SAKing Abdulaziz Medical City · SAKing Khalid University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFosfomycin has been used more frequently in managing uncomplicated urinary tract infections (UTIs) due to decreased compliance and increased multidrug-resistant bacteria. The aim of this network meta-analysis was to assess the efficacy of Fosfomycin compared to Nitrofurantoin, Trimethoprim-Sulfamethoxazole (TMP-SMX), and Ciprofloxacin in terms of clinical and microbiological cure alongside with other measurements. MATERIALS AND

methodsWe searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL). We included randomized control trials (RCTs) with uncomplicated UTI patients who received Fosfomycin, Nitrofurantoin, TMP-SMX, or Ciprofloxacin and reported the clinical or microbiological cure. We used Cochrane Risk of Bias Assessment Tool to assess the included studies' quality. R-software was used for all statistical analysis. We ranked all antibiotics using the netrank function which yielded P scores. Frequentist network meta-analysis was used to assess the efficacy of all outcomes.

resultsWe included 13 RCTs with a total number of 3856 patients that showed Fosfomycin ranked the highest among the other antibiotics with respect to clinical cure (P-score = 0.99) and microbiological cure (P-score = 0.99) while Ciprofloxacin ranked the lowest (P-score = 0.11 and 0.02, respectively). Moreover, Ciprofloxacin yielded the highest relapse rate (P-score = 1), whereas TMP-SMX had the lowest relapse rate (P-score = 0.07). As for the adverse events, Ciprofloxacin demonstrated the highest adverse events as opposed to Fosfomycin (P-score = 0.98 and 0.05, respectively).

conclusionThe network meta-analysis demonstrated that Fosfomycin is the most effective antibiotic in treating uncomplicated UTIs with respect to clinical cure, microbiological cure, and adverse events profile.

Indexed as

FosfomycinUrinary Tract InfectionsAnti-Bacterial AgentsCiprofloxacinHumansNitrofurantoinRecurrenceTrimethoprim, Sulfamethoxazole Drug CombinationAnti-Bacterial AgentsCiprofloxacinFosfomycinNitrofurantoinTrimethoprim, Sulfamethoxazole Drug CombinationCiprofloxacinFosfomycinNitrofurantoinTrimethoprim–SulfamethoxazoleUrinary tract infection

Identifiers

PMID38587648
OpenAlexW4394578878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.